Former CEO and Founder, Esther Alegria, Remains on Executive Team Focused on Driving Research & Development Through External Collaborations
APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
Presentation at IPF Summit Elucidates APT-101 Mechanism of Action
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis
APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research
APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer
APIE Therapeutics appoints Robert Willette, Ph.D. to the newly created role of chief scientific officer.